Search


Vicore Pharma is leveraging its understanding of the Renin-Angiotensin System (RAS) to develop angiotensin II type 2 receptor agonists for IPF and beyond
CEO Ahmed Mousa walks us through the sciences and describes how data stacked up against a synthetic external control that was presented at a medical meeting this summer. Coverage brought to you by
5 days ago


Vicore Pharma's CEO describes the rationale for using angiotensin II type 2 receptor agonists in IPF
Ahmed Mousa describes what excited him to join the company from the U.S. one year ago, the unmet need that still exists in this large...
Sep 19, 2024








.png)




